Pipeline

1
Pipeline HCV

• UK-CAB 31 January 2009

2
Pipeline

• TMC435 Hepatitis C
• Phase II-a, small cohorts, cohort 5. News _at_ EASL
• Phase II-b later in 2009
• RSV353 (Respiratory Syncitial Virus)
• Phase I

3
Hepatitis C Telaprevir.

• Co-development with VERTEX.
• Sponsored and managed by Vertex
• 1050 Treatment-naïve patients.
• Sponsored and managed by TIBOTEC
• 650 Treatment-failure patients

4
Studies for HIV/HCV coinfected patients

• DDI studies ongoing. Tenofovir no significant
  interaction
• Coinfection study pilot study will start this
  year
• Synopsis of protocol has been sent to ECAB for
  review
• US Community has seen and commented